LUPIN - Swing Trade Analysis with AI Signals
← Back to ListKey Parameters
⭐ Swing Trade Rating: 4.2
Show all parameters (20 more)
🧾 Trade Setup
Entry Price: 2,145 ₹. Optimal Exit Strategy: Target a profit taking exit at 2,300 ₹, utilizing the high of 2,530 ₹ as an initial resistance level. Alternatively, hold for another week to observe reaction to USFDA findings, aiming for a target of 2,250₹ before considering a wider sell-off. Overall Verdict: This presents a compelling swing trading opportunity given the recent earnings strength and relatively low valuation relative to its peers, but diligent monitoring of the USFDA situation is paramount.
✅ Positive
The stock is exhibiting strong recent profit growth with a PAT increase of 76% quarter-over-quarter and a robust ROCE of 26.2%. Furthermore, the RSI indicates relatively low bearish momentum at 35.1, suggesting potential for upward movement.
⚠️ Limitation
Despite solid earnings, the Stock P/E of 14.9 is lower than the Industry PE of 34.8, indicating a discount relative to its peers. This could represent an opportunity but also reflects potential downside risk if growth doesn’t continue or expectations are revised downward.
📉 Company Negative News
Recent news indicates the USFDA raised observations at the Somerset facility, potentially creating short-term uncertainty and triggering selling pressure. A Business Standard article reports Lupin Ltd down for fifth straight session, suggesting continued negative sentiment.
📈 Company Positive News
The stock price rose 2.04% following positive valuation, peer and sector updates, reflecting investor confidence in the company’s performance.
🏭 Industry
The pharmaceutical sector is currently experiencing moderate volatility driven by regulatory changes and patent expirations. While Lupin has demonstrated strong growth, broader industry headwinds could still impact sentiment.